abiraterone,olaparib
astrazeneca,merck
['crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel']
os data from propel (olaparib + abi) in 1st line mcrpc. 7 mo median os benefit (p=0.054). but really driven by hrrm subgroup, right? #gu23 
Jack Lapides, M.D., Research Professor and Chief of Urologic Oncology @UMichUrology @umichmedicine | Associate Editor @EUplatinum | Views Mine